EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A “Prime and Expand” strategy using the multifunctional fusion proteins to generate memory-like NK cells for cell therapy

Niraj Shrestha, Michael J Dee, Pallavi Chaturvedi, Gilles M Leclerc, Mary Mathyer, Celeste Dufour, Laura Arthur, Michelle Becker-Hapak, Mark Foster, Ethan McClain, Natalia Valderrama Pena, Karen Kage und 14 weitere

Cancer Immunology, Immunotherapy · 2024

DOI: 10.1007/s00262-024-03765-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2024. Verfasst von Niraj Shrestha und 25 weiteren Autor:innen. Beteiligte Einrichtung: HCW Biologics Inc., 2929 N. Commerce Parkway, Miramar, FL, 33025, USA. Hauptthemen laut MEDLINE: Killer Cells, Natural, Recombinant Fusion Proteins, Immunologic Memory. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, HCW Biologics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adoptive cellular therapy (ACT) using memory-like (ML) natural killer (NK) cells, generated through overnight ex vivo activation with IL-12, IL-15, and IL-18, has shown promise for treating hematologic malignancies. We recently reported that a multifunctional fusion molecule, HCW9201, comprising IL-12, IL-15, and IL-18 domains could replace individual cytokines for priming human ML NK cell programming (“Prime” step). However, this approach does not include ex vivo expansion, thereby limiting the ability to test different doses and schedules. Here, we report the design and generation of a multifunctional fusion molecule, HCW9206, consisting of human IL-7, IL-15, and IL-21 cytokines. We observed > 300-fold expansion for HCW9201-primed human NK cells cultured for 14 days with HCW9206 and HCW9101, an IgG1 antibody, recognizing the scaffold domain of HCW9206 (“Expand” step). This expansion was dependent on both HCW9206 cytokines and interactions of the IgG1 mAb with CD16 receptors on NK cells. The resulting “Prime and Expand” ML NK cells exhibited elevated metabolic capacity, stable epigenetic IFNG promoter demethylation, enhanced antitumor activity in vitro and in vivo, and superior persistence in NSG mice. Thus, the “Prime and Expand” strategy represents a simple feeder cell-free approach to streamline manufacturing of clinical-grade ML NK cells to support multidose and off-the-shelf ACT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Killer Cells, NaturalRecombinant Fusion ProteinsImmunologic MemoryHumansAnimalsMiceCell- and Tissue-Based TherapyImmunotherapy, AdoptiveInterleukin-15

Stichwörter der Autor:innen

Adoptive cell therapyCytokine-induced memory like NK cells, IL-7, IL-12, IL-15, IL-18, IL-21NK cellsPrime and Expand

Substanzen

Recombinant Fusion ProteinsInterleukin-15

Autor:innen und Institutionen

  • HCW Biologics Inc., 2929 N. Commerce Parkway, Miramar, FL, 33025, USA.
  • Wugen, Inc., Saint Louis, MO, 63108, USA.
  • Division of Oncology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO, 63110, USA.
  • HCW Biologics Inc., 2929 N. Commerce Parkway, Miramar, FL, 33025, USA. hingwong@hcwbiologics.com.

Förderung

  • NCI NIH HHS
  • NIH HHS
  • HCW Biologics
  • Wugen
  • NIH
  • Paula C and Rodger O. Riney Blood Cancer Initiative

Zitieren

APA

Shrestha, N., Dee, M. J., Chaturvedi, P., Leclerc, G. M., Mathyer, M., Dufour, C., Arthur, L., Becker-Hapak, M., Foster, M., McClain, E., Pena, N. V., Kage, K., Zhu, X., George, V., Liu, B., Egan, J., Echeverri, C., Wang, M., You, L., …, & Wong, H. C. (2024). A “Prime and Expand” strategy using the multifunctional fusion proteins to generate memory-like NK cells for cell therapy. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03765-8

Vancouver

Shrestha N, Dee MJ, Chaturvedi P, Leclerc GM, Mathyer M, Dufour C, et al. A “Prime and Expand” strategy using the multifunctional fusion proteins to generate memory-like NK cells for cell therapy. Cancer Immunology, Immunotherapy. 2024. doi:10.1007/s00262-024-03765-8

BibTeX
@article{Shrestha2024,
  author = {Shrestha, Niraj and Dee, Michael J and Chaturvedi, Pallavi and Leclerc, Gilles M and Mathyer, Mary and Dufour, Celeste and Arthur, Laura and Becker-Hapak, Michelle and Foster, Mark and McClain, Ethan and Pena, Natalia Valderrama and Kage, Karen and Zhu, Xiaoyun and George, Varghese and Liu, Bai and Egan, Jack and Echeverri, Christian and Wang, Meng and You, Lijing and Kong, Lin and Li, Liying and Berrien-Elliott, Melissa M and Cooper, Matthew L and Fehniger, Todd A and Rhode, Peter R and Wong, Hing C},
  title = {A “Prime and Expand” strategy using the multifunctional fusion proteins to generate memory-like NK cells for cell therapy},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2024},
  doi = {10.1007/s00262-024-03765-8}
}
Kostenlos starten →